F
Fabrice Barlesi
Researcher at Aix-Marseille University
Publications - 666
Citations - 36214
Fabrice Barlesi is an academic researcher from Aix-Marseille University. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 64, co-authored 582 publications receiving 25403 citations. Previous affiliations of Fabrice Barlesi include Institut Gustave Roussy & Nord University.
Papers
More filters
Journal ArticleDOI
Mathematical Modeling of Cancer Immunotherapy and Its Synergy with Radiotherapy.
Raphaël Serre,Sebastien Benzekry,Laetitia Padovani,Christophe Meille,Nicolas André,Joseph Ciccolini,Fabrice Barlesi,Xavier Muracciole,Dominique Barbolosi +8 more
TL;DR: In this article, a discrete-time pharmacodynamic model of the combination of radiotherapy with inhibitors of the PD1-PDL1 axis and/or the CTLA4 pathway is described.
Journal ArticleDOI
Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer.
Fabrice Barlesi,Céline Gimenez,Jean-Philippe Torre,Christophe Doddoli,Julien Mancini,L. Greillier,François Roux,Jean-Pierre Kleisbauer +7 more
TL;DR: Combining Cyfra 21-1, NSE and CEA combined as prognostic factors in advanced stage non-small cell lung cancer patients correlated with prognosis in a significant and independent manner.
Journal ArticleDOI
Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer (NSCLC) patients.
David Planchard,Julien Mazieres,Gregory J. Riely,Charles M. Rudin,Fabrice Barlesi,Elisabeth Quoix,Pierre Jean Souquet,Mark A. Socinski,Julie Switzky,Bo Ma,Vicki L. Goodman,Stanley W. Carson,C. Martin Curtis,Michael R. W. Streit,Bruce E. Johnson +14 more
TL;DR: Interim efficacy and safety data obtained in 17 BRAF V600E–mutant NSCLC patients enrolled in dabrafenib phase II study BRF113928 are reported.
Journal ArticleDOI
Biomarkers (BM) France: Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts).
Fabrice Barlesi,Hélène Blons,Michèle Beau-Faller,Isabelle Rouquette,L'Houcine Ouafik,Jean Mosser,Jean-Philippe Merlio,Pierre Paul Bringuier,Philippe Jonveaux,Cédric Le Maréchal,Marc G. Denis,Frédérique Penault-Llorca,Didier Debieuvre,Jean-Charles Soria,Jacques Cadranel,Julien Mazieres,P. Missy,Franck Morin,Frederique Nowak,Gérard Zalcman,Intergroupe Francophone de Cancerologie Thoracique +20 more
TL;DR: 10,000 BM analyses were collected and entered into the BM France database at the time of this first analysis, and on the basis of available data, the patients were mainly male, (ex)smokers and stage IV pts and tumors were mainly adenocarcinomas.
Journal ArticleDOI
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial
Denis Moro-Sibilot,Nathalie Cozic,Maurice Pérol,Julien Mazieres,J. Otto,P.J. Souquet,Ratislav Bahleda,Marie Wislez,Gérard Zalcman,Gérard Zalcman,S.D. Guibert,Fabrice Barlesi,Bertrand Mennecier,Isabelle Monnet,Renaud Sabatier,S. Bota,C. Dubos,V. Verriele,Véronique Haddad,Gilbert Ferretti,Alexis B. Cortot,F. De Fraipont,Marta Jimenez,N. Hoog-Labouret,Gilles Vassal +24 more
TL;DR: There are signs of late response not sufficient to justify the development of crizotinib in patients with ROS1-translocated tumours, but the continued targeting of c-MET with innovative therapies appears justified.